Korean J Gynecol Oncol.  2007 Jun;18(2):108-113.

Concurrent chemoradiation therapy in cervical cancer with para-aortic lymph node involvement

• Shin JW
• Lee KC
• Lee SH
• Choi JH
• Lee KB
• Park CY

Abstract

OBJECTIVE
This study was undertaken to evaluate the therapeutic results and complications after concurrent chemoradiation therapy and to investigate the prognostic factors for cervical cancer with para-aortic lymph node involvement.
METHODS
From May 1999 to August 2005, thirty eight patients with cervical cancer, treated by combined platinum base chemotherapy and extended field radiation therapy in Gachon University Gil medical center. All patients were diagnosed as paraaortic lymphnode involvement with imaging studies. The radiation dose of external beam was 34.2-64.4 Gy to whole pelvis and 32.4-59.4 Gy to paraaortic area. Cisplatin based chemotherapy was done simultaneously. We evaluated the prognostic factors such as stage, tumor size, inguinal and supraclavicular lymphnode status, and radiation doses.
RESULTS
Median follow-up period is 34 months (7-85 months). The 3 year overall and disease free survival rates were 63.6% and 56.4%, respectively. There was no case of recurrence after 3 years of treatment. In 2 patients, the treatment was not completed because of Grade III or IV gastroenteral complications; abdominal pain and diarrhea. Grade III or IV hematologic complications were occurred in fifteen patients, but all patients were recovered without serious complications. We could not find any significant prognostic factors in this study.
CONCLUSION
Concurrent chemoradiation therapy for cervical cancer with paraaortic lymph node involvement is well tolerable and effective treatment.

Keyword

Cervical cancer; Para-aortic lymph node; Chemoradiation therapy

MeSH Terms

Abdominal Pain
Cisplatin
Diarrhea
Disease-Free Survival
Drug Therapy
Follow-Up Studies
Humans
Lymph Nodes*
Pelvis
Platinum
Recurrence
Uterine Cervical Neoplasms*
Cisplatin
Platinum